Actelion Ltd (ALIOF) 174.2800 $ALIOF Dr. Reddy's (RDY)

New Post Public Reply Private Reply Replies (0) Message Board

Jul 27, 2016 at 12:12 PM

Actelion Ltd (ALIOF) 174.2800 $ALIOF

Dr. Reddy's (RDY) Q1 Earnings and Revenues Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:10AM CDT
Dr. Reddy's (RDY) reported first-quarter fiscal 2017 earnings per American Depositary Share of 11 cents, down 79.6% from the year-ago quarter.
RDY: 44.37 (+0.26), BMY: 75.99 (+0.93)

Seattle Genetics' (SGEN) Loss Narrower than Expected in Q2
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:06AM CDT
Seattle Genetics (SGEN) reported a loss of 23 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 33 cents.
SGEN: 46.69 (+2.92), BMY: 75.99 (+0.93)

After GILD Earnings, Which Biomed Stock is Best Right Now?
Ryan McQueeney - Zacks Investment Research - Tue Jul 26, 3:55PM CDT
For many investors, Gilead is the go-to stock in the biomed industry. However, with revenues looking sluggish this year, these three Zacks Rank #1 (Strong Buy) stocks might end up being a better bet.
INVA: 11.90 (+0.46), GILD: 81.55 (+0.50), ANIP: 60.35 (+0.86)

Actelion (ALIOF) Beats Q2 Earnings & Revenues, View Up
Zacks Equity Research - Zacks Investment Research - Fri Jul 22, 12:13PM CDT
Actelion (ALIOF) reported second-quarter 2016 earnings of $2.13 per American Depository Receipt, up from the year-ago figure of $1.60.
INVA: 11.90 (+0.46), SNY: 42.15 (+0.04), NKTR: 15.23 (+0.08)

Medical Stocks to Post Earnings This Week: ABT, BIIB, ALIOF
Zacks Equity Research - Zacks Investment Research - Tue Jul 19, 9:06AM CDT
Medical is one of the few sectors that are poised to report earnings growth this quarter. While the sector's second-quarter earnings are projected to improve 0.5%, revenues are expected to grow 7.7%.
BIIB: 287.90 (+0.86), ABT: 43.49 (-0.11), NVS: 82.56 (-0.46)

3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 17.81 (+0.47), GILD: 81.55 (+0.50), MRK: 58.40 (+0.04), UTHR: 113.25 (+0.80)

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved
Globe Newswire - Wed May 04, 5:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 33.54 (+0.10), UTHR: 113.25 (+0.80), AEGR: 1.44 (unch)

Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio
Globe Newswire - Thu Apr 21, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Clovis Hits 52-week Low Post Rociletinib Briefing Documents
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 2:45PM CDT
Clovis Oncology's (CLVS) shares touched a 52-week low with the FDA raising concerns related to the lung cancer treatment, rociletinib, in its briefing documents.
EBS: 33.54 (+0.10), CLVS: 14.27 (+0.31), ANIK: 52.03 (+0.20)

Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 3:40PM CDT
Ionis Pharmaceuticals' (IONS) shares plunged 11% after the FDA placed a clinical hold on the phase III CARDIO-TTR study on IONIS-TTRRx.
BIIB: 287.90 (+0.86), GSK: 44.91 (+0.75), IONS: 28.60 (+0.41)

Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.61 (unch), SCMP: 11.85 (+0.32), ICPT: 164.50 (+4.91)

Illumina Unveils BaseSpace Suite, Boosts Precision Medicine
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 12:55PM CDT
Illumina, Inc. (ILMN) recently launched its BaseSpace Informatics suite to facilitate precision medicine and genomics research.
ILMN: 162.27 (+12.17), AMAG: 26.85 (+1.90), ANIK: 52.03 (+0.20)

Seres Therapeutics (MCRB) in Focus: Stock Up 5.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:35AM CDT
Seres Therapeutics, Inc. (MCRB) was a big mover last session, as the company saw its shares rise around 6% on the day.
MCRB: 35.15 (+0.27)

Ironwood Slumps, Halts Development of Gastroparesis Drug
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:10AM CDT
Ironwood Pharmaceuticals (IRWD) plans to discontinue the development of IW-9179 for diabetic gastroparesis after unfavorable phase IIa study results; shares fall.
IRWD: 14.47 (+0.32), EBS: 33.54 (+0.10), AMAG: 26.85 (+1.90)

Actelion issues invitation to 2016 Annual General Meeting of Shareholders
Globe Newswire - Wed Apr 06, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2016 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

AbbVie Up, Wins CHMP Backing for Humira's Expanded Use
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 10:20AM CDT
AbbVie Inc. (ABBV) announced that the EMA's CHMP has rendered an opinion in favor of expanding Humira's label in the EU.
EBS: 33.54 (+0.10), ABBV: 64.70 (+0.25), AMAG: 26.85 (+1.90)

Abeona Therapeutics (ABEO) Jumps: Stock Rises 6.4%
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:40AM CDT
Abeona Therapeutics Inc. (ABEO) saw its shares rise above 6% in the last trading session.
ABEO: 2.48 (-0.06)

Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 3:10PM CDT
Bristol-Myers' (BMY) Opdivo gets CHMP backing for label expansion of Opdivo in combination with Yervoy for advanced (unresectable or metastatic) melanoma.
AMAG: 26.85 (+1.90), BMY: 75.99 (+0.93), ANIK: 52.03 (+0.20)

Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 2:40PM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi's atopic dermatitis candidate dupilumab scores in phase III studies; shares up.
AMAG: 26.85 (+1.90), SNY: 42.15 (+0.04), REGN: 409.63 (+11.36)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Quorum Joins LIVE Coalition to Revolutionize Estate Planning

Shaking Up Estate Planning: Quorum Joins LIVE Coalition Here's a fresh shake-up in the world of estate planning. Quorum Federal Credit Union has thrown its hat into the ring as the latest member of the LIVE Coalition, a band of financial, legal, and tech wizards putting estate plans on a modern track. This marks them as the 70th player to dive into this alliance, pushing...

Fiber Giants Unite to Boost Connectivity in Montana

Montana's Broadband Transformation Takes a Leap Folks in Northwest Montana, take note. Vero Fiber and MontanaSky have tied the knot, officially sealing a merger that doesn't just unite two reputable broadband providers but promises to shake up the internet game across the region. Just ask anyone who's tried to stream a movie during peak hours in Flathead Valley. A...

MiniCo's New Desk: A Game Changer for E&S Market

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...

Nukleus Launches Unified Platform for Athletes' Business

Leveling the Business Field for Athletes Athletes spend their lives fighting for every inch on the field, and now Nukleus is giving them the tools to hold ground off it. Why should they be the last ones to know their own business? Ashton Jeanty and Nukleus got tired of that narrative and kicked off a platform today with a real promise: putting an athlete's entire business...

Nelson-Jameson Boosts Cold Storage in California Move

An Icy Boost for the West Coast Dairy Player Every now and then, a company gets its cold storage game just right. Nelson-Jameson has added fresh muscle to its Turlock facility in California, making waves with serious logistical upgrades. The company's dogged pursuit of better operational efficiency in dairy processing isn't just about bragging rights. It's plain old good...

Li-Fire Expands Fire Safety Amid Rising Battery Risks

A Crunchy Look at New Fire Safety Moves Well, folks, here's a twist we didn't see coming but sure makes sense in today's electrifying business landscape. Li-Fire, the big brains behind lithium battery fire suppression, is spreading its wings nationwide, or at least its wholesale and distribution programs are. And right ahead of National Fire Safety Week no less—talk...

Sports Research Joins Costco: Creatine Mix Available

Breaking Into the Big League: Sports Research Hits Costco When a company's product finds its way onto Costco's shelves, you know they're not just playing in the minor leagues anymore. This October, Sports Research® made a bold move into the retail giant's sports nutrition section with their new Creatine + Electrolytes powder. It's not their first rodeo when it comes to...

Comparent Unveils Key Insights with Top 100 List

The Ebb and Flow of Vacation Rental Giants Ever noticed how some industries just sneak up and suddenly transform landscapes? Vacation rental management is one of those sneaky offenders. At the forefront of keeping tabs on this bustling sector, Comparent just dropped a meaty second annual roster—the Comparent 100—showcasing the biggest players flexing their muscles in...

Mitsubishi's Q3 Sales: SUVs Up, Mirage Out

You ever notice how the market treats innovation and tradition like they’re these ever-spinning plates in a circus act? Take Mitsubishi Motors North America (MMNA). Their third-quarter report's got me both nodding in approval and scratching my head. Sure, they sold 18,543 vehicles—down 5.6% from the previous year. But don’t write 'em off just yet. The slumping...

Cannatrol and Veterans Nonprofit Unite for Healing

Veterans Find a New Ally in Cannabis Tech When two distinct worlds collide for a cause, it can create waves of change much bigger than simple collaboration. That's exactly what's happening with Cannatrol and Operation Green Healing, a partnership that could redefine support for our veterans. Cannatrol, renowned for its groundbreaking post-harvest cannabis technology, has...